Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT00634088 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Accrual

Conditions

Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
DRUG: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
DRUG: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
DRUG: Ixabepilone + Lapatinib + Capecitabine

Sponsor

R-Pharm

Collaborators

[object Object]